On August 27, Moderna, Inc. declined 4.01% in regular trading, trading at $144.845/share with turnover of $590 million, after the company announced a plan to offer $2 billion worth of convertible senior notes due 2032 through a private placement.

Moderna disclosed that it will grant initial purchasers a 13-day option to acquire up to an additional $300 million in notes. The company expects to use net proceeds to pay the cost of associated capped call transactions and for general corporate purposes. Moderna also announced plans to purchase a capped call overlay instrument to offset potential dilution, with the cap initially set at a minimum of 150% premium to the stock price at pricing.

The offering comes amid a period of extreme volatility for the stock, which surged approximately 177% earlier this month following positive Phase III results for its personalized mRNA cancer vaccine intismeran autogene developed with Merck, before experiencing a 23.5% pullback and subsequent rebounds. Multiple Wall Street firms had raised target prices in recent sessions, with the stock still in a price discovery phase. The convertible notes issuance signals the company is capitalizing on elevated share prices to strengthen its balance sheet, though the potential dilutive effect weighed on investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)